Financials CALYXTPAR

Equities

CLXT

US13173L2060

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq 06:00:00 2024-02-04 pm EST 5-day change 1st Jan Change
17.59 USD -.--% Intraday chart for CALYXTPAR +2.93% -10.44%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 231 156.4 82.02 7.204 372.1 342.5 - -
Enterprise Value (EV) 1 191 147.2 82.02 7.204 372.1 342.5 342.5 342.5
P/E ratio -5.79 x -3.2 x -2.73 x -0.4 x -0.76 x -5.23 x -7.02 x -11.3 x
Yield - - - - - - - -
Capitalization / Revenue 31.7 x 6.56 x 3.16 x 45.9 x 205 x 162 x 41.1 x 7.58 x
EV / Revenue 31.7 x 6.56 x 3.16 x 45.9 x 205 x 162 x 41.1 x 7.58 x
EV / EBITDA -6.07 x -4.94 x -3.3 x -0.43 x -7.64 x -6.96 x -5.26 x -6.19 x
EV / FCF -6,614,793 x -3,440,853 x - - - - - -
FCF Yield -0% -0% - - - - - -
Price to Book 3.68 x 3.88 x - - - - - -
Nbr of stocks (in thousands) 659 741 770 977 18,946 21,623 - -
Reference price 2 350.5 211.0 106.5 7.375 19.64 15.84 15.84 15.84
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7.296 23.85 25.99 0.157 1.817 2.117 8.34 45.16
EBITDA 1 -38.07 -31.64 -24.86 -16.84 -48.68 -49.2 -65.15 -55.36
EBIT 1 -39.67 -43.83 -29.33 -22.37 -69.46 -66.77 -68.46 -37.55
Operating Margin -543.76% -183.77% -112.87% -14,248.41% -3,823% -3,153.36% -820.84% -83.15%
Earnings before Tax (EBT) 1 -39.61 -44.84 -29.2 -16.89 -337.6 -89.72 -94.42 -64.04
Net income 1 -39.61 -44.84 -29.2 -16.89 -267.6 -84.29 -87.52 -60.69
Net margin -542.93% -187.98% -112.36% -10,758.6% -14,729.06% -3,980.78% -1,049.36% -134.41%
EPS 2 -60.50 -66.00 -39.00 -18.50 -25.95 -3.030 -2.255 -1.405
Free Cash Flow -34.92 -45.46 - - - - - -
FCF margin -478.62% -190.59% - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 7.762 1.943 0.032 0.041 0.042 0.042 - 0.475 1.103 0.395 0.44 0.484 0.532
EBITDA 1 -6.941 -5.273 -4.895 -4.932 -4.61 -1.829 - -18.28 -13.65 -20.26 -18.45 -17.46 -17.7
EBIT 1 -6.957 -6.71 -6.089 -6.765 -6.203 -3.313 - -25.8 -19.89 -21.87 -19.97 -18.9 -19.05
Operating Margin -89.63% -345.34% -19,028.12% -16,500% -14,769.05% -7,888.1% - -5,430.95% -1,803.54% -5,537.47% -4,539.32% -3,905.58% -3,581.2%
Earnings before Tax (EBT) 1 -7.307 -7.057 -5.619 -2.485 -5.95 -2.837 - -34.53 -277.2 -30.13 -28.27 -27.24 -27.43
Net income 1 -7.307 -7.057 -5.619 -2.485 -5.95 -2.837 -18.69 -26.43 -217.1 -30.13 -28.27 -27.24 -27.43
Net margin -94.14% -363.2% -17,559.38% -6,060.98% -14,166.67% -6,754.76% - -5,564% -19,683.95% -7,626.84% -6,424.32% -5,627.69% -5,155.64%
EPS 2 -10.00 -9.000 -6.500 -2.500 -6.500 -3.000 -3.050 -1.590 -19.62 -1.010 -0.9500 -0.8300 -0.8400
Dividend per Share - - - - - - - - - - - - -
Announcement Date 11/4/21 3/3/22 5/5/22 8/4/22 11/3/22 3/2/23 8/10/23 11/9/23 3/21/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 40 9.24 - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -34.9 -45.5 - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 95.30 54.40 - - - - - -
Cash Flow per Share -48.70 -64.40 - - - - - -
Capex 2.97 1.79 - - - - - -
Capex / Sales 40.69% 7.49% - - - - - -
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/21/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
15.84 USD
Average target price
23 USD
Spread / Average Target
+45.20%
Consensus